Safety and Efficacy of Amlotinib in the Treatment of Recurrent Craniopharyngioma
Status:
RECRUITING
Trial end date:
2028-04-20
Target enrollment:
Participant gender:
Summary
Primary Aim:
To assess the objective remission rate (ORR) of patients with recurrent craniopharyngiomas treated with amrlotinib .
Secondary Aims:
1. To assess progression-free survival (PFS) and overall survival (OS) of patients with recurrent craniopharyngiomas treated with amrlotinib.
2. To analyze the disease control rate (DCR) of the Anrotinib treatment regimen in patients with recurrent craniopharyngiomas, including the proportion of patients in complete remission, partial remission and stable disease.
3. Monitor and evaluate the safety of amrutinib, especially the occurrence of drug-related adverse events (AEs) .